Clinical Trials Browser

Phase 3 × Has announcements × Lenalidomide × Clear all

NCT04404283 2026-03-17

ECHELON-3

Phase 3 Active not recruiting

238 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03710603 2026-02-10

Perseus

Phase 3 Active not recruiting

709 enrolled 17 charts 1 FDA

Multiple Myeloma

NCT03652064 2026-01-20

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Phase 3 Active not recruiting

395 enrolled 1 FDA

Multiple Myeloma

NCT04680052 2025-12-22

InMIND

Phase 3 Active not recruiting

654 enrolled 40 charts 1 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT02252172 2025-10-20

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

737 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT05409066 2025-07-28

EPCORE FL-1

Phase 3 Active not recruiting

549 enrolled 2 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT01996865 2025-07-10

MAGNIFY

Phase 3 Completed

503 enrolled 18 charts 1 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03319667 2024-11-27

IMROZ

Phase 3 Active not recruiting

475 enrolled 1 FDA

Multiple Myeloma

NCT01938001 2023-02-22

AUGMENT

Phase 3 Completed

358 enrolled 18 charts 1 FDA

Lymphoma, Non-Hodgkin